USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. Lactation Advise not to breastfeed. (8.2) Renal Impairment Monitor patients with severe renal impairment (creatinine clearance less than 30 mL/min) for toxicity when treated with arsenic trioxide injection; dose reduction may be warranted. (8.6)Hepatic Impairment Monitor patients with severe hepatic impairment (Child-Pugh Class C) for toxicity when treated with arsenic trioxide injection. (8.7). Lactation Advise not to breastfeed. (8.2) Renal Impairment Monitor patients with severe renal impairment (creatinine clearance less than 30 mL/min) for toxicity when treated with arsenic trioxide injection; dose reduction may be warranted. (8.6). Hepatic Impairment Monitor patients with severe hepatic impairment (Child-Pugh Class C) for toxicity when treated with arsenic trioxide injection. (8.7). 8.1 Pregnancy. Risk SummaryBased on the mechanism of action [see Clinical Pharmacology (12.1)] and findings in animal studies, arsenic trioxide injection can cause fetal harm when administered to pregnant woman. Arsenic trioxide was embryolethal and teratogenic in rats when administered on gestation day at dose approximately 10 times the recommended human daily dose on mg/m basis (see Data). related trivalent arsenic, sodium arsenite, produced teratogenicity when administered during gestation in mice at dose approximately times the projected human dose on mg/m basis and in hamsters at an intravenous dose approximately equivalent to the projected human daily dose on mg/m2 basis. There are no studies with the use of arsenic trioxide injection in pregnant women, and limited published data on arsenic trioxide use during pregnancy are insufficient to inform drug-associated risk of major birth defects and miscarriage. Advise pregnant women of the potential risk to fetus.The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.Data Human Data One patient was reported to deliver live infant with no reported congenital anomalies after receiving arsenic trioxide during the first five months of pregnancy. second patient became pregnant three months after discontinuing arsenic trioxide and was reported to have normal pregnancy outcome. third patient was pregnant healthcare provider who experienced dermal contact with liquid arsenic trioxide and had normal pregnancy outcome after treatment and monitoring. fourth patient who became pregnant while receiving arsenic trioxide had miscarriage.Animal Data Studies in pregnant mice, rats, hamsters, and primates have shown that inorganic arsenicals cross the placental barrier when given orally or by injection. An increase in resorptions, neural-tube defects, anophthalmia and microphthalmia were observed in rats administered 10 mg/kg of arsenic trioxide on gestation day (approximately 10 times the recommended human daily dose on mg/m2 basis). Similar findings occurred in mice administered 10 mg/kg dose of related trivalent arsenic, sodium arsenite (approximately times the projected human dose on mg/m2 basis), on gestation days 6, 7, 8, or 9. Intravenous injection of mg/kg sodium arsenite (approximately equivalent to the projected human daily dose on mg/m2 basis) on gestation day (the lowest dose tested) resulted in neural-tube defects in hamsters. 8.2 Lactation. Risk SummaryArsenic trioxide is excreted in human milk. There are no data on the effects of arsenic trioxide on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed child, advise women not to breastfeed during treatment with arsenic trioxide injection and for weeks after the final dose.. 8.3 Females and Males of Reproductive Potential. Arsenic trioxide injection can cause fetal harm when administered to pregnant woman [see Use in Specific Populations (8.1)]. Pregnancy TestingConduct pregnancy testing in females of reproductive potential prior to initiation of arsenic trioxide injection.ContraceptionFemalesAdvise females of reproductive potential to use effective contraception during treatment with arsenic trioxide injection and for months after the final dose.MalesAdvise males with female partners of reproductive potential to use effective contraception during treatment with arsenic trioxide injection and for months after the final dose.InfertilityMalesBased on testicular toxicities including decreased testicular weight and impaired spermatogenesis observed in animal studies, arsenic trioxide injection may impair fertility in males of reproductive potential [see Nonclinical Toxicology (13.1)].. 8.4 Pediatric Use. The safety and efficacy of arsenic trioxide injection as single agent for treatment of pediatric patients with relapsed or refractory APL is supported by the pivotal phase study in 40 patients with relapsed or refractory APL. Five patients below the age of 18 years (age range: to 16 years) were treated with arsenic trioxide injection at the recommended dose of 0.15 mg/kg/day. literature review included an additional 17 patients treated with arsenic trioxide for relapsed or refractory APL, with ages ranging from to 21 years. No differences in efficacy and safety were observed by age.. 8.5 Geriatric Use. Use of arsenic trioxide injection as monotherapy in patients with relapsed or refractory APL is supported by the open-label, single-arm trial that included patients aged 65 and older (range: 65 to 73 years). literature review included an additional patients aged 69 to 72 years who were treated with arsenic trioxide for relapsed or refractory APL. No overall differences in safety or effectiveness were observed between these patients and younger patients.. 8.6 Renal Impairment. Exposure of arsenic trioxide may be higher in patients with severe renal impairment [see Clinical Pharmacology (12.3)]. Monitor patients with severe renal impairment (creatinine clearance [CLcr] less than 30 mL/min) frequently for toxicity; dose reduction may be warranted. The use of arsenic trioxide injection in patients on dialysis has not been studied. 8.7 Hepatic Impairment. Since limited data are available across all hepatic impairment groups, caution is advised in the use of arsenic trioxide injection in patients with hepatic impairment [see Clinical Pharmacology (12.3)]. Monitor patients with severe hepatic impairment (Child-Pugh Class C) frequently for toxicity.

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. Hepatotoxicity: Monitor hepatic function tests at least twice weekly during induction and at least once weekly during consolidation. Withhold arsenic trioxide injection for certain elevations in AST, alkaline phosphatase and bilirubin and resume at reduced dose upon resolution. (2.3, 5.4)Carcinogenesis: Arsenic trioxide is human carcinogen. Monitor patients for the development of second primary malignancies. (5.5)Embryo-Fetal Toxicity: Can cause fetal harm. Advise of potential risk to fetus and use of effective contraception. (5.6, 8.1, 8.3). Hepatotoxicity: Monitor hepatic function tests at least twice weekly during induction and at least once weekly during consolidation. Withhold arsenic trioxide injection for certain elevations in AST, alkaline phosphatase and bilirubin and resume at reduced dose upon resolution. (2.3, 5.4). Carcinogenesis: Arsenic trioxide is human carcinogen. Monitor patients for the development of second primary malignancies. (5.5). Embryo-Fetal Toxicity: Can cause fetal harm. Advise of potential risk to fetus and use of effective contraception. (5.6, 8.1, 8.3). 5.1 Differentiation Syndrome. Differentiation syndrome, which may be life-threatening or fatal, has been observed in patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide injection. In clinical trials, 16-23% of patients treated with arsenic trioxide injection for APL developed differentiation syndrome. Signs and symptoms include unexplained fever, dyspnea, hypoxia, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusion, weight gain, peripheral edema, hypotension, renal insufficiency, hepatopathy and multi-organ dysfunction. Differentiation syndrome has been observed with and without concomitant leukocytosis, and it has occurred as early as day of induction to as late as the second month induction therapy. If differentiation syndrome is suspected, temporarily withhold arsenic trioxide injection and immediately initiate dexamethasone 10 mg intravenously every 12 hours and hemodynamic monitoring until resolution of signs and symptoms for minimum of days [see Dosage and Administration (2.3)]. 5.2 Cardiac Conduction Abnormalities. Patients treated with arsenic trioxide injection can develop QTc prolongation, torsade de pointes, and complete atrioventricular block. In the clinical trials of patients with relapsed or refractory APL treated with arsenic trioxide injection monotherapy, 40% had at least one ECG tracing with QTc interval greater than 500 msec. prolonged QTc was observed between and weeks after start of arsenic trioxide injection infusion, and it usually resolved by weeks after arsenic trioxide injection infusion. There are no data on the effect of arsenic trioxide injection on the QTc interval during the infusion of the drug.The risk of torsade de pointes is related to the extent of QTc prolongation, concomitant administration of QTc prolonging drugs, history of torsade de pointes, pre-existing QTc interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. The risk may be increased when arsenic trioxide injection is coadministered with medications that can lead to electrolyte abnormalities (such as diuretics or amphotericin B) [see Drug Interactions (7)].Prior to initiating therapy with arsenic trioxide injection, assess the QTc interval by electrocardiogram, correct pre-existing electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval. Do not administer arsenic trioxide injection to patients with ventricular arrhythmia or prolonged QTc. If possible, discontinue drugs that are known to prolong the QTc interval. If it is not possible to discontinue the interacting drug, perform cardiac monitoring frequently [see Drug Interactions (7)]. During arsenic trioxide injection therapy, maintain potassium concentrations above mEq/L and magnesium concentrations above 1.8 mg/dL. Monitor ECG weekly and more frequently for clinically unstable patients.For patients who develop QTc Framingham greater than 450 msec for men or greater than 460 msec for women, withhold arsenic trioxide injection and any medication known to prolong the QTc interval. Correct electrolyte abnormalities. When the QTc normalizes and electrolyte abnormalities are corrected, resume arsenic trioxide injection at reduced dose [see Dosage and Administration (2.3)]. 5.3 Encephalopathy. Serious encephalopathies were reported in patients receiving arsenic trioxide injection. Monitor patients for neurological symptoms, such as confusion, decreased level of consciousness, seizures, cognitive deficits, ataxia, visual symptoms and ocular motor dysfunction. Advise patients and caregivers of the need for close observation.Wernickes Encephalopathy Wernickes encephalopathy occurred in patients receiving arsenic trioxide injection. Wernickes encephalopathy is neurologic emergency that can be prevented and treated with thiamine. Consider testing thiamine levels in patients at risk for thiamine deficiency (e.g., chronic alcohol use, malabsorption, nutritional deficiency, concomitant use of furosemide). Administer parenteral thiamine in patients with or at risk for thiamine deficiency. Monitor patients for neurological symptoms and nutritional status while receiving arsenic trioxide injection. If Wernickes encephalopathy is suspected, immediately interrupt arsenic trioxide injection and initiate parenteral thiamine. Monitor until symptoms resolve or improve and thiamine levels normalize.. 5.4 Hepatotoxicity. During treatment with arsenic trioxide injection, monitor hepatic function tests at least twice weekly during induction and at least once weekly during consolidation. Withhold arsenic trioxide injection if elevations in AST or alkaline phosphatase occur to greater than times the upper limit of normal and/or elevation in serum total bilirubin occurs to greater than times the upper limit of normal and resume at reduced dose upon resolution [see Dosage and Administration (2.3)].. 5.5 Carcinogenesis. The active ingredient of arsenic trioxide injection, arsenic trioxide, is human carcinogen. Monitor patients for the development of second primary malignancies. 5.6 Embryo-Fetal Toxicity. Arsenic trioxide injection can cause fetal harm when administered to pregnant woman. Arsenic trioxide was embryolethal and teratogenic in rats when administered on gestation day at dose approximately 10 times the recommended human daily dose on mg/m2 basis. related trivalent arsenic, sodium arsenite, produced teratogenicity when administered during gestation in mice at dose approximately times the projected human dose on mg/m2 basis and in hamsters at an intravenous dose approximately equivalent to the projected human daily dose on mg/m2 basis. Advise pregnant women of the potential risk to fetus. Advise females of reproductive potential to use effective contraception during treatment with arsenic trioxide injection and for months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with Arsenic trioxide injection and for months after the last dose [see Use in Specific Populations (8.1, 8.3)].

ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. The following clinically significant adverse reactions are described elsewhere in the labeling.Differentiation Syndrome [see Warnings and Precautions (5.1)] Cardiac Conduction Abnormalities [see Warnings and Precautions (5.2)] Encephalopathy[see Warnings and Precautions (5.3)] Hepatotoxicity [see Warnings and Precautions (5.4)] Carcinogenesis [see Warnings and Precautions (5.5)] Differentiation Syndrome [see Warnings and Precautions (5.1)] Cardiac Conduction Abnormalities [see Warnings and Precautions (5.2)] Encephalopathy[see Warnings and Precautions (5.3)] Hepatotoxicity [see Warnings and Precautions (5.4)] Carcinogenesis [see Warnings and Precautions (5.5)] The most common adverse reactions (> 30%) are nausea, cough, fatigue, pyrexia, headache, abdominal pain, vomiting, tachycardia, diarrhea, dyspnea, hypokalemia, leukocytosis, hyperglycemia, hypomagnesemia, insomnia, dermatitis, edema, QTc prolongation, rigors, sore throat, arthralgia, paresthesia, and pruritus (6.1).To report SUSPECTED ADVERSE REACTIONS, contact Ingenus Pharmaceuticals, LLC at 1-877-748-1970 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Relapsed or Refractory APLSafety information was available for 52 patients with relapsed or refractory APL who participated in clinical trials of arsenic trioxide injection. Forty patients in the Study PLRXAS01 received the recommended dose of 0.15 mg/kg, of whom 28 completed both induction and consolidation cycles. An additional 12 patients with relapsed or refractory APL received doses generally similar to the recommended dose. Serious adverse reactions observed in the 40 patients with refractory or relapsed APL enrolled in Study PLRXAS01 included differentiation syndrome (n=3), hyperleukocytosis (n=3), QTc interval >= 500 msec (n=16, with torsade de pointes), atrial dysrhythmias (n=2), and hyperglycemia (n=2). The most common adverse reactions (> 30%) were nausea, cough, fatigue, pyrexia, headache, abdominal pain, vomiting, tachycardia, diarrhea, dyspnea, hypokalemia, leukocytosis, hyperglycemia, hypomagnesemia, insomnia, dermatitis, edema, QTc prolongation, rigors, sore throat, arthralgia, paresthesia, and pruritus.Table describes the adverse reactions in patients aged to 73 years with APL who received arsenic trioxide injection at the recommended dose. Similar adverse reactions profiles were seen in the other patient populations who received arsenic trioxide injection. Table 5: Adverse Reactions (>= 5%) in Patients with Relapsed or Refractory APL Who Received Arsenic Trioxide Injection in Study PLRXAS01 Body System Adverse reaction Any Grade Adverse Reactions Grade >=3 Adverse Reactions % % Gastrointestinal disorders Nausea 30 75 Abdominal pain (lower upper) 23 58 10 Vomiting 23 58 Diarrhea 21 53 Sore throat 14 35 Constipation 11 28 3 Anorexia 23 Appetite decreased 15 Loose stools 10 Dyspepsia 10 Oral blistering 8 Fecal incontinence 8 Gastrointestinal hemorrhage 8 Dry mouth 8 Abdominal tenderness 8 Diarrhea hemorrhagic 8 Abdominal distension 8 Respiratory Cough 26 65 Dyspnea 21 53 10 Epistaxis 10 25 Hypoxia 23 10 Pleural effusion 20 3 Post nasal drip 13 Wheezing 13 Decreased breath sounds 10 Crepitations 10 Rales 10 Hemoptysis 8 Tachypnea 8 Rhonchi 8 General disorders and administration site conditions Fatigue 25 63 5 Pyrexia (fever) 25 63 5 Edema non-specific 16 40 Rigors 15 38 Chest pain 10 25 5 Injection site pain 20 Pain non-specific 15 3 Injection site erythema 13 Weight gain 13 Injection site edema 10 Weakness 10 5 Hemorrhage 8 Weight loss 8 Drug hypersensitivity 5 3 Nervous system disorders Headache 24 60 3 Insomnia 17 43 3 Paresthesia 13 33 5 Dizziness (excluding vertigo) 23 Tremor 13 Convulsion 8 5 Somnolence 8 Coma 5 5 Cardiac disorders Tachycardia 22 55 ECG QT corrected interval prolonged 500 msec 16 40 Palpitations 10 ECG abnormal other than QT interval prolongation 8 Metabolism and nutrition disorders Hypokalemia 20 50 13 Hypomagnesemia 18 45 13 Hyperglycemia 18 45 13 ALT increased 20 5 Hyperkalemia 18 5 AST increased 13 3 Hypocalcemia 10 Hypoglycemia 8 Acidosis 5 Hematologic disorders Leukocytosis 20 50 3 Anemia 20 5 Thrombocytopenia 18 13 Febrile neutropenia 13 8 Neutropenia 10 10 Disseminated intravascular coagulation 8 8 Lymphadenopathy 8 Skin and subcutaneous tissue disorders Dermatitis 17 43 Pruritus 13 33 3 Ecchymosis 20 Dry skin 15 Erythema non-specific 13 Increased sweating 13 Facial edema 8 Night sweats 8 Petechiae 8 Hyperpigmentation 8 Non-specific skin lesions 8 Urticaria 8 Local exfoliation 5 Eyelid edema 5 Musculoskeletal, connective tissue, and bone disorders Arthralgia 13 33 8 Myalgia 10 25 5 Bone pain 23 10 Back pain 18 3 Neck pain 13 Pain in limb 13 5 Psychiatric disorders Anxiety 12 30 Depression 20 Agitation 5 Confusion 5 Vascular disorders Hypotension 10 25 5 Flushing 10 Hypertension 10 Pallor 10 Infections and infestations Sinusitis 20 Herpes simplex 13 Upper respiratory tract infection 13 3 Bacterial infection non- specific 8 3 Herpes zoster 8 Nasopharyngitis 5 Oral candidiasis 5 Sepsis 5 5 Reproductive system disorders Vaginal hemorrhage 13 Intermenstrual bleeding 8 Ocular disorders Eye irritation 10 Blurred vision 10 Dry eye 8 Painful red eye 5 Renal and urinary disorders Renal failure 8 3 Renal impairment 8 Oliguria 5 Incontinence 5 Ear disorders Earache 8 Tinnitus 5 Other Clinically Relevant Adverse ReactionsLeukocytosis: Arsenic trioxide injection can induce proliferation of leukemic promyelocytes resulting in rapid increase in white blood cell count. Leukocytosis greater than 10 Gi/L developed during induction therapy in 50% of patients receiving arsenic trioxide injection monotherapy for relapsed/refractory APL. In the relapsed/refractory setting, relationship did not exist between baseline WBC counts and development of hyperleukocytosis nor baseline WBC counts and peak WBC counts. 6.2 Postmarketing Experience. The following adverse reactions have been identified during postapproval use of Arsenic trioxide injection. Because these reactions are reported voluntarily from population of uncertain size, it is not always possible to reliably estimate the frequency or establish causal relationship to drug exposure. Cardiac disorders: Ventricular extrasystoles in association with QT prolongation, ventricular tachycardia in association with QT prolongation, including torsade de pointes, atrioventricular block, and congestive heart failureEar and labyrinth disorders: Deafness Hematologic disorders: Pancytopenia, bone marrow necrosisInfections: Herpes zosterInvestigations: Gamma-glutamyltransferase increasedMusculoskeletal and connective tissue disorders: Bone pain, myalgia, rhabdomyolysisNeoplasms benign, malignant and unspecified: Melanoma, pancreatic cancer, squamous cell carcinomaNervous system disorders: Peripheral neuropathy, paresis, seizures, confusion, encephalopathy, Wernickes encephalopathy, posterior reversible encephalopathy syndromeSkin and subcutaneous tissue disorders: Toxic epidermal necrolysis.

BOXED WARNING SECTION.

WARNING: DIFFERENTIATION SYNDROME, CARDIAC CONDUCTIONABNORMALITIES AND ENCEPHALOPATHY INCLUDING WERNICKES. Differentiation Syndrome: Patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide injection have experienced differentiation syndrome, which may be life-threatening or fatal. Signs and symptoms may include unexplained fever, dyspnea, hypoxia, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, weight gain, peripheral edema, hypotension, renal insufficiency, hepatopathy, and multi-organ dysfunction, in the presence or absence of leukocytosis. If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. Temporarily withhold arsenic trioxide injection [see Dosage and Administration (2.3), Warnings and Precautions (5.1)]. Cardiac Conduction Abnormalities: Arsenic trioxide injection can cause QTc interval prolongation, complete atrioventricular block and torsade de pointes, which can be fatal. Before administering arsenic trioxide injection, assess the QTc interval, correct electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval. Do not administer arsenic trioxide injection to patients with ventricular arrhythmia or prolonged QTc interval. Withhold arsenic trioxide injection until resolution and resume at reduced dose for QTc prolongation [see Dosage and Administration (2.3), Warnings and Precautions (5.2)] Encephalopathy: Serious encephalopathy, including Wernickes, has occurred with arsenic trioxide injection. Wernickes is neurologic emergency. Consider testing thiamine levels in patients at risk for thiamine deficiency. Administer parenteral thiamine in patients with or at risk for thiamine deficiency. Monitor patients for neurological symptoms and nutritional status while receiving arsenic trioxide injection. If Wernickes encephalopathy is suspected, immediately interrupt arsenic trioxide injection and initiate parenteral thiamine. Monitor until symptoms resolve or improve and thiamine levels normalize [see Warnings and Precautions (5.3)].. WARNING: DIFFERENTIATION SYNDROME, CARDIAC CONDUCTION ABNORMALITIES, and ENCEPHALOPATHY INCLUDING WERNICKESSee full prescribing information for complete boxed warning. Patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide injection have experienced symptoms of differentiation syndrome, which may be life-threatening or fatal. If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. Temporarily withhold arsenic trioxide injection. (2.3, 5.1) Arsenic trioxide injection can cause QTc interval prolongation, complete atrioventricular block and torsade de pointes, which can be fatal. Before administering arsenic trioxide injection, assess the QTc interval, correct electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval. Do not administer arsenic trioxide injection to patients with ventricular arrhythmia or prolonged QTc interval. Withhold arsenic trioxide injection until resolution and resume at reduced dose for QTc prolongation. (2.3, 5.2) Serious encephalopathy, including Wernickes, has occurred with arsenic trioxide injection. If Wernickes encephalopathy is suspected, immediately interrupt arsenic trioxide injection and initiate parenteral thiamine. Monitor until symptoms resolve or improve and thiamine levels normalize. (5.3) Patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide injection have experienced symptoms of differentiation syndrome, which may be life-threatening or fatal. If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. Temporarily withhold arsenic trioxide injection. (2.3, 5.1) Arsenic trioxide injection can cause QTc interval prolongation, complete atrioventricular block and torsade de pointes, which can be fatal. Before administering arsenic trioxide injection, assess the QTc interval, correct electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval. Do not administer arsenic trioxide injection to patients with ventricular arrhythmia or prolonged QTc interval. Withhold arsenic trioxide injection until resolution and resume at reduced dose for QTc prolongation. (2.3, 5.2) Serious encephalopathy, including Wernickes, has occurred with arsenic trioxide injection. If Wernickes encephalopathy is suspected, immediately interrupt arsenic trioxide injection and initiate parenteral thiamine. Monitor until symptoms resolve or improve and thiamine levels normalize. (5.3).

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. The mechanism of action of arsenic trioxide injection is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein promyelocytic leukemia (PML)-retinoic acid receptor (RAR)-alpha.. 12.2 Pharmacodynamics. Cardiac Electrophysiology In single-arm trial of Arsenic trioxide injection (0.15 mg/kg daily), 16 of 40 patients (40%) had QTc interval greater than 500 msec. Prolongation of the QTc was observed between and weeks after arsenic trioxide injection infusion, and then returned towards baseline by the end of weeks after arsenic trioxide injection infusion.. 12.3 Pharmacokinetics. The inorganic, lyophilized form of arsenic trioxide, when placed into solution, immediately forms the hydrolysis product arsenious acid (AsIII). AsIII is the pharmacologically active species of arsenic trioxide. Monomethylarsonic acid (MMAV), and dimethylarsinic acid (DMAV) are the main pentavalent metabolites formed during metabolism, in addition to arsenic acid (AsV) product of AsIII oxidation. The pharmacokinetics of arsenical species ([AsIII], [AsV], [MMAV], [DMAV]) were determined in APL patients following once-daily doses of 0.15 mg/kg for days per week. Over the total single-dose range of to 32 mg (administered as 0.15 mg/kg), systemic exposure (AUC) appears to be linear. Peak plasma concentrations of arsenious acid (AsIII), the primary active arsenical species were reached at the end of infusion (2 hours). Plasma concentration of AsIII declined in biphasic manner with mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by slower terminal elimination phase. The daily exposure to AsIII (mean AUC0-24h) was 194 ng.hr/mL (n=5) on Day of Cycle and 332 ng.hr/mL (n=6) on Day 25 of Cycle 1, which represents an approximate 2-fold accumulation. The primary pentavalent metabolites, MMAVand DMAV, are slow to appear in plasma (approximately 10 to 24 hours after first administration of arsenic trioxide), but, due to their longer half-life, accumulate more upon multiple dosing than does AsIII. The mean estimated terminal elimination half-lives of the metabolites MMAVand DMAVare 32 hours and 72 hours, respectively. Approximate accumulation ranged from 1.4- to 8-fold following multiple dosing as compared to single-dose administration. AsV is present in plasma only at relatively low levels. Distribution The volume of distribution (Vss) for AsIII is large (mean 562 L, N=10) indicating that AsIII is widely distributed throughout body tissues. Vss is also dependent on body weight and increases as body weight increases. EliminationMetabolism Much of the AsIII is distributed to the tissues where it is methylated to the less cytotoxic metabolites, monomethylarsonic acid (MMAV) and dimethylarsinic acid (DMAV) by methyltransferases primarily in the liver. The metabolism of arsenic trioxide also involves oxidation of AsIII to AsV, which may occur in numerous tissues via enzymatic or nonenzymatic processes. AsV is present in plasma only at relatively low levels following administration of arsenic trioxide. Excretion Approximately 15% of the administered arsenic trioxide injection dose is excreted in the urine as unchanged AsIII. The methylated metabolites of AsIII (MMAV, DMAV) are primarily excreted in the urine. The total clearance of AsIII is 49 L/h and the renal clearance is L/h. Clearance is not dependent on body weight or dose administered over the range of to 32 mg. Specific PopulationsPatients with Renal Impairment The effect of renal impairment on the pharmacokinetics of AsIII, AsV, and the pentavalent metabolites MMAV and DMAVwas evaluated in 20 patients with advanced malignancies. Patients were classified as having normal renal function (creatinine clearance [CLcr] 80 mL/min, n=6), mild renal impairment (CLcr 50 to 80 mL/min, n=5), moderate renal impairment (CLcr 30 to 49 mL/min, n=6), or severe renal impairment (CLcr 30 mL/min, n=3). Following twice-weekly administration of 0.15 mg/kg over 2-hour infusion, the mean AUC0-INF for AsIII was comparable among the normal, mild and moderate renal impairment groups. However, in the severe renal impairment group, the mean AUC0-INF for AsIII was approximately 48% higher than that in the normal group. Systemic exposure to MMAV and DMAV tended to be larger in patients with renal impairment; however, the clinical consequences of this increased exposure are not known. AsV plasma levels were generally below the limit of assay quantitation in patients with impaired renal function [see Use in Specific Populations (8.6)]. The use of arsenic trioxide in patients on dialysis has not been studied. Patients with Hepatic Impairment The effect of pharmacokinetics of AsIII, AsV, and the pentavalent metabolites MMAV and DMAV was evaluated following administration of 0.25 to 0.50 mg/kg of arsenic trioxide in patients with hepatocellular carcinoma. Patients were classified as having normal hepatic function (n=4), mild hepatic impairment (Child-Pugh class A, n=12), moderate hepatic impairment (Child-Pugh class B, n=3), or severe hepatic impairment (Child-Pugh class C, n=1). No clear trend toward an increase in systemic exposure to AsIII, AsV, MMAV or DMAV was observed with decreasing level of hepatic function as assessed by dose-normalized (per mg dose) AUC in the mild and moderate hepatic impairment groups. However, the one patient with severe hepatic impairment had mean dose-normalized AUC0-24h and Cmax values 40% and 70% higher, respectively, than those patients with normal hepatic function. The mean dose-normalized trough plasma levels for both MMAV and DMAV in this severely hepatically impaired patient were 2.2-fold and 4.7-fold higher, respectively, than those in the patients with normal hepatic function [see Use in Specific Populations (8.7)]. Pediatric Patients Following intravenous administration of 0.15 mg/kg/day of arsenic trioxide in 10 APL patients (median age 13.5 years, range 4-20 years), the daily exposure to AsIII (mean AUC0-24h) was 317 ng.hr/mL on Day of Cycle [see Use in Specific Populations (8.4)]. Drug Interaction StudiesNo formal assessments of pharmacokinetic drug-drug interactions between arsenic trioxide injection and other drugs have been conducted. The methyltransferases responsible for metabolizing arsenic trioxide are not members of the cytochrome P450 family of isoenzymes. In vitro incubation of arsenic trioxide with human liver microsomes showed no inhibitory activity on substrates of the major cytochrome P450 (CYP) enzymes such as 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4/5, and 4A9/11. The pharmacokinetics of drugs that are substrates for these CYP enzymes are not expected to be affected by concomitant treatment with arsenic trioxide.

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES. 14.2 Relapsed or Refractory APL. Arsenic trioxide injection was investigated in Study PLRXAS01, an open-label, single-arm trial in 40 patients with relapsed or refractory APL who were previously treated with an anthracycline and retinoid regimen. Patients received arsenic trioxide injection 0.15 mg/kg/day intravenously over to hours until the bone marrow was cleared of leukemic cells or for maximum of 60 days. The CR (absence of visible leukemic cells in bone marrow and peripheral recovery of platelets and white blood cells with confirmatory bone marrow >= 30 days later) rate in this population of previously treated patients was 28 of 40 (70%). Among the 22 patients who had relapsed less than one year after treatment with tretinoin, there were 18 complete responders (82%). Of the 18 patients receiving arsenic trioxide injection >= one year from tretinoin treatment, there were 10 complete responders (55%). The median time to bone marrow remission was 44 days and to onset of CR was 53 days. Three of children, years or older, achieved CR. No children less than years old were treated.Three to six weeks following bone marrow remission, 31 patients received consolidation therapy with arsenic trioxide injection, at the same dose, for 25 additional days over period up to weeks. In follow-up treatment, 18 patients received further arsenic trioxide injection as maintenance course. Fifteen patients had bone marrow transplants. At last follow-up, 27 of 40 patients were alive with median follow-up time of 484 days (range 280 to 755) and 23 of 40 patients remained in complete response with median follow-up time of 483 days (range 280 to 755).Cytogenetic conversion to no detection of the APL chromosome rearrangement was observed in 24 of 28 (86%) patients who met the response criteria defined above, in of (100%) patients who met some, but not all, of the response criteria, and of (43%) of patients who did not respond. RT-PCR conversions to no detection of the APL gene rearrangement were demonstrated in 22 of 28 (79%) of patients who met the response criteria, in of (60%) of patients who met some, but not all, of the response criteria, and in of (29%) of patients who did not respond.Responses were seen across all age groups tested, ranging from to 72 years. The ability to achieve CR was similar for both sexes. There were insufficient patients of Black, Hispanic, or Asian ancestry to estimate relative response rates in these groups, but responses were seen in each group.

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. Relapsed or refractory APL:Induction Administer 0.15 mg/kg/day intravenously daily until bone marrow remission. Do not exceed 60 days. (2.2)Consolidation: Administer 0.15 mg/kg/day intravenously daily for 25 doses over period of up to weeks. (2.2). Induction Administer 0.15 mg/kg/day intravenously daily until bone marrow remission. Do not exceed 60 days. (2.2). Consolidation: Administer 0.15 mg/kg/day intravenously daily for 25 doses over period of up to weeks. (2.2). 2.2 Recommended Dosage for Relapsed or Refractory APL. treatment course for patients with relapsed or refractory APL consists of induction cycle and consolidation cycle [see Clinical Studies (14.2)]. For the induction cycle, the recommended dosage of arsenic trioxide injection is 0.15 mg/kg/day intravenously daily until bone marrow remission or up to maximum of 60 days. For the consolidation cycle, the recommended dosage of arsenic trioxide injection is 0.15 mg/kg/day intravenously daily for 25 doses over period of up to weeks. Begin consolidation to weeks after completion of induction cycle.. For the induction cycle, the recommended dosage of arsenic trioxide injection is 0.15 mg/kg/day intravenously daily until bone marrow remission or up to maximum of 60 days.. For the consolidation cycle, the recommended dosage of arsenic trioxide injection is 0.15 mg/kg/day intravenously daily for 25 doses over period of up to weeks. Begin consolidation to weeks after completion of induction cycle.. 2.3 Monitoring and Dosage Modifications for Adverse Reactions. During induction, monitor coagulation studies, blood counts, and chemistries at least 2-3 times per week through recovery. During consolidation, monitor coagulation studies, blood counts, and chemistries at least weekly. Table shows the dosage modifications for adverse reactions due to arsenic trioxide injection when used alone. Table 2: Dosage Modifications for Adverse Reactions of Arsenic Trioxide Injection Adverse Reaction Dosage Modification Differentiation syndrome, defined by the presence of or more of the following: Unexplained fever Dyspnea Pleural and/or pericardial effusion Pulmonary infiltrates Renal failure Hypotension Weight gain greater than kg [see Warnings and Precautions (5.1)] Temporarily withhold arsenic trioxide injection. Administer dexamethasone 10 mg intravenously every 12 hours until the resolution of signs and symptoms for minimum of days. Resume treatment when the clinical condition improves and reduce the dose of the withheld drug(s) by 50%. Increase the dose of the withheld drug(s) to the recommended dosage after one week in the absence of recurrence of symptoms of differentiation syndrome. If symptoms re-appear, decrease arsenic trioxide injection to the previous dose. QTc (Framingham formula) Prolongation greater than 450 msec for men or greater than 460 msec for women [see Warnings and Precautions (5.2)]. Withhold arsenic trioxide injection and any medication known to prolong the QTc interval. Correct electrolyte abnormalities. After the QTc normalizes and electrolyte abnormalities are corrected, resume treatment with arsenic trioxide injection at 50% reduced dose (0.075 mg/kg/day daily) for one week after resolution. If the 50% reduced dose is tolerated for one week (in the absence of QTc prolongation), increase the dose of arsenic trioxide injection to 0.11 mg/kg/day daily for the next week. The dose of arsenic trioxide injection can be increased to 0.15 mg/kg/day in the absence of QTc prolongation during that 14-day dose-escalation period. Hepatotoxicity, defined by or more of the following: Total bilirubin (TB) greater than times the upper limit of normal (ULN) Aspartate aminotransferase (AST) greater than times the ULN Alkaline phosphatase (AP) greater than times the ULN [see Warnings and Precautions (5.4)] Withhold arsenic trioxide injection. Resume treatment at 50% reduced dose of the withheld drug(s) when TB is less than 1.5 times the ULN and AP/AST are less than times the ULN. Increase the dose of the withheld drug(s) back to the recommended dosage after one week on the reduced dose in the absence of worsening of hepatotoxicity. Discontinue the withheld drug(s) permanently if hepatotoxicity recurs. Other severe or life- threatening (grade 3-4) nonhematologic reactions [see Adverse Reactions (6)] Temporarily withhold arsenic trioxide injection. When the adverse reaction resolves to no more than mild (grade 1), resume arsenic trioxide injection reduced by dose levels (see Table below). Moderate (grade 2) nonhematologic reactions [see Adverse Reactions (6)] Reduce the dose of arsenic trioxide injection by dose level (see Table below). Leukocytosis (WBC count greater than 10 Gi/L) [see Adverse Reactions (6.1)] Administer hydroxyurea. Hydroxyurea may be discontinued when the WBC declines below 10 Gi/L. Myelosuppression, defined by or more of the following: absolute neutrophil count less than Gi/L platelets less than 50 Gi/L lasting more than weeks [see Adverse Reactions (6)] Consider reducing the dose of arsenic trioxide injection by dose level (see Table below). If myelosuppression lasts >= 50 days or occurs on consecutive cycles, assess marrow aspirate for remission status. In the case of molecular remission, resume arsenic trioxide injection at dose level lower (see Table below). Table 3: Dose Reduction Levels for Hematologic and Nonhematologic Toxicities Dose Level Arsenic trioxide injection mg/kg intravenously once daily Starting level 0.15 -1 0.11 -2 0.10 -3 0.075 2.4 Preparation and Administration. Reconstitution Dilute arsenic trioxide injection with 100 to 250 mL 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP, using proper aseptic technique, immediately after withdrawal from the vial. Do not save any unused portions for later administration. After dilution, store arsenic trioxide injection for no more than 24 hours at room temperature and 48 hours when refrigerated.Administration Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.Administer arsenic trioxide injection as an intravenous infusion over hours. The infusion duration may be extended up to hours if acute vasomotor reactions are observed. central venous catheter is not required.The arsenic trioxide injection vial is single-dose and does not contain any preservatives. Discard unused portions of each vial properly. Do not mix arsenic trioxide injection with other medications. Safe Handling Procedures Arsenic trioxide injection is hazardous drug. Follow applicable special handling and disposal procedures.1.

INFORMATION FOR PATIENTS SECTION.

17 PATIENT COUNSELING INFORMATION. Differentiation Syndrome Advise patients that symptoms of APL differentiation syndrome include fever, sudden weight gain, dizziness/lightheadedness, labored breathing, and accumulation of fluid in the lungs, heart, and chest. This syndrome is managed by immediate treatment with high-dose corticosteroids. Advise patients to immediately report any of these symptoms [see Warnings and Precautions (5.1)]. Cardiac Conduction AbnormalitiesAdvise patients that arsenic trioxide injection may cause ECG abnormalities, including QT prolongation. If extreme, this prolongation has the potential to cause fainting, irregular heartbeat, or more serious side effects. Advise patients to immediately report any of these symptoms. Advise patients to provide complete list of current medications as caution should be taken when arsenic trioxide injection is coadministered with other medications that can cause QT prolongation or lead to electrolyte abnormalities [see Warnings and Precautions (5.2) and Drug Interactions (7)]. Encephalopathy and Wernickes Encephalopathy (WE) Advise patients that symptoms of encephalopathies include neurological symptoms such as confusion, decreased level of consciousness, seizures, cognitive deficits, ataxia, visual symptoms and ocular motor dysfunction. Advise patients and caregivers to closely monitor for neurological symptoms and immediately report them to their healthcare provider [see Warnings and Precautions (5.3)]. Advise patients at risk for thiamine deficiency (e.g., chronic alcohol use, malabsorption, nutritional deficiency, concomitant use of furosemide) that Wernickes encephalopathy is neurologic emergency that can be prevented and treated with thiamine supplementation, and to immediately report any neurological symptoms to their healthcare provider [see Warnings and Precautions (5.3)]. Embryo-Fetal Toxicity Advise pregnant women of the potential risk to fetus. Advise females of reproductive potential to inform their healthcare provider of known or suspected pregnancy [see Warnings and Precautions (5.5) and Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during treatment with arsenic trioxide injection and for months after the last dose [see Use in Specific Populations (8.3)]. Advise males with female partners of reproductive potential to use effective contraception during treatment with arsenic trioxide injection for months after the last dose [see Use in Specific Populations (8.3)]. Lactation Advise women not to breastfeed during treatment with arsenic trioxide injection and for weeks after the last dose [see Use in Specific Populations (8.2)]. Infertility Advise males of reproductive potential that arsenic trioxide injection may impair fertility [see Use in Specific Population (8.3)]. Other Adverse Reactions Advise patients of the expected adverse reactions of arsenic trioxide injection. Most patients in clinical trials experienced some drug-related toxicity, most commonly leukocytosis, gastrointestinal symptoms (nausea, vomiting, diarrhea, and abdominal pain), fatigue, edema, hyperglycemia, dyspnea, cough, rash or itching, headaches, and dizziness. Advise patients to call their healthcare provider at the onset of any adverse reactions [see Adverse Reactions (6.1)]. Rx only Manufactured for:Ingenus Pharmaceuticals, LLCOrlando, FL 32839-6408Made in SwitzerlandRevised: 11/2020. Ingenus Logo.

NONCLINICAL TOXICOLOGY SECTION.

13 NONCLINICAL TOXICOLOGY. 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. Carcinogenicity studies have not been conducted with arsenic trioxide injection [see Warnings and Precautions (5.6)]. Arsenic trioxide and trivalent arsenite salts have not been demonstrated to be mutagenic to bacteria, yeast, or mammalian cells. Arsenite salts are clastogenic in vitro (human fibroblast, human lymphocytes, Chinese hamster ovary cells, Chinese hamster V79 lung cells). Trivalent arsenic was genotoxic in the chromosome aberrations assay and micronucleus bone marrow assay in mice. The effect of arsenic on fertility has not been adequately studied in humans. Decreased testicular weight and impaired spermatogenesis have been reported in animal studies. Male Wistar rat pups were administered 1.5 mg/kg sodium arsenite solution via the intraperitoneal route from postnatal days to 14 and testes were collected for evaluation on postnatal days 15, 21, and 50. Results of this study revealed an altered morphology of the seminiferous tubules along with degeneration of spermatogenic cells, increased number of sperm with abnormal morphology, and decreased sperm counts. In beagle dogs administered intravenous arsenic trioxide for 90 days, reduced inner cell layers within seminiferous tubules and significantly decreased numbers of spermatocytes, spermatozoa, and sperm cells were observed at doses of mg/kg/day and higher. The mg/kg/day dose is approximately times the recommended human daily dose on mg/m2 basis.

PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. The inorganic, lyophilized form of arsenic trioxide, when placed into solution, immediately forms the hydrolysis product arsenious acid (AsIII). AsIII is the pharmacologically active species of arsenic trioxide. Monomethylarsonic acid (MMAV), and dimethylarsinic acid (DMAV) are the main pentavalent metabolites formed during metabolism, in addition to arsenic acid (AsV) product of AsIII oxidation. The pharmacokinetics of arsenical species ([AsIII], [AsV], [MMAV], [DMAV]) were determined in APL patients following once-daily doses of 0.15 mg/kg for days per week. Over the total single-dose range of to 32 mg (administered as 0.15 mg/kg), systemic exposure (AUC) appears to be linear. Peak plasma concentrations of arsenious acid (AsIII), the primary active arsenical species were reached at the end of infusion (2 hours). Plasma concentration of AsIII declined in biphasic manner with mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by slower terminal elimination phase. The daily exposure to AsIII (mean AUC0-24h) was 194 ng.hr/mL (n=5) on Day of Cycle and 332 ng.hr/mL (n=6) on Day 25 of Cycle 1, which represents an approximate 2-fold accumulation. The primary pentavalent metabolites, MMAVand DMAV, are slow to appear in plasma (approximately 10 to 24 hours after first administration of arsenic trioxide), but, due to their longer half-life, accumulate more upon multiple dosing than does AsIII. The mean estimated terminal elimination half-lives of the metabolites MMAVand DMAVare 32 hours and 72 hours, respectively. Approximate accumulation ranged from 1.4- to 8-fold following multiple dosing as compared to single-dose administration. AsV is present in plasma only at relatively low levels. Distribution The volume of distribution (Vss) for AsIII is large (mean 562 L, N=10) indicating that AsIII is widely distributed throughout body tissues. Vss is also dependent on body weight and increases as body weight increases. EliminationMetabolism Much of the AsIII is distributed to the tissues where it is methylated to the less cytotoxic metabolites, monomethylarsonic acid (MMAV) and dimethylarsinic acid (DMAV) by methyltransferases primarily in the liver. The metabolism of arsenic trioxide also involves oxidation of AsIII to AsV, which may occur in numerous tissues via enzymatic or nonenzymatic processes. AsV is present in plasma only at relatively low levels following administration of arsenic trioxide. Excretion Approximately 15% of the administered arsenic trioxide injection dose is excreted in the urine as unchanged AsIII. The methylated metabolites of AsIII (MMAV, DMAV) are primarily excreted in the urine. The total clearance of AsIII is 49 L/h and the renal clearance is L/h. Clearance is not dependent on body weight or dose administered over the range of to 32 mg. Specific PopulationsPatients with Renal Impairment The effect of renal impairment on the pharmacokinetics of AsIII, AsV, and the pentavalent metabolites MMAV and DMAVwas evaluated in 20 patients with advanced malignancies. Patients were classified as having normal renal function (creatinine clearance [CLcr] 80 mL/min, n=6), mild renal impairment (CLcr 50 to 80 mL/min, n=5), moderate renal impairment (CLcr 30 to 49 mL/min, n=6), or severe renal impairment (CLcr 30 mL/min, n=3). Following twice-weekly administration of 0.15 mg/kg over 2-hour infusion, the mean AUC0-INF for AsIII was comparable among the normal, mild and moderate renal impairment groups. However, in the severe renal impairment group, the mean AUC0-INF for AsIII was approximately 48% higher than that in the normal group. Systemic exposure to MMAV and DMAV tended to be larger in patients with renal impairment; however, the clinical consequences of this increased exposure are not known. AsV plasma levels were generally below the limit of assay quantitation in patients with impaired renal function [see Use in Specific Populations (8.6)]. The use of arsenic trioxide in patients on dialysis has not been studied. Patients with Hepatic Impairment The effect of pharmacokinetics of AsIII, AsV, and the pentavalent metabolites MMAV and DMAV was evaluated following administration of 0.25 to 0.50 mg/kg of arsenic trioxide in patients with hepatocellular carcinoma. Patients were classified as having normal hepatic function (n=4), mild hepatic impairment (Child-Pugh class A, n=12), moderate hepatic impairment (Child-Pugh class B, n=3), or severe hepatic impairment (Child-Pugh class C, n=1). No clear trend toward an increase in systemic exposure to AsIII, AsV, MMAV or DMAV was observed with decreasing level of hepatic function as assessed by dose-normalized (per mg dose) AUC in the mild and moderate hepatic impairment groups. However, the one patient with severe hepatic impairment had mean dose-normalized AUC0-24h and Cmax values 40% and 70% higher, respectively, than those patients with normal hepatic function. The mean dose-normalized trough plasma levels for both MMAV and DMAV in this severely hepatically impaired patient were 2.2-fold and 4.7-fold higher, respectively, than those in the patients with normal hepatic function [see Use in Specific Populations (8.7)]. Pediatric Patients Following intravenous administration of 0.15 mg/kg/day of arsenic trioxide in 10 APL patients (median age 13.5 years, range 4-20 years), the daily exposure to AsIII (mean AUC0-24h) was 317 ng.hr/mL on Day of Cycle [see Use in Specific Populations (8.4)]. Drug Interaction StudiesNo formal assessments of pharmacokinetic drug-drug interactions between arsenic trioxide injection and other drugs have been conducted. The methyltransferases responsible for metabolizing arsenic trioxide are not members of the cytochrome P450 family of isoenzymes. In vitro incubation of arsenic trioxide with human liver microsomes showed no inhibitory activity on substrates of the major cytochrome P450 (CYP) enzymes such as 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4/5, and 4A9/11. The pharmacokinetics of drugs that are substrates for these CYP enzymes are not expected to be affected by concomitant treatment with arsenic trioxide.

PREGNANCY SECTION.

8.1 Pregnancy. Risk SummaryBased on the mechanism of action [see Clinical Pharmacology (12.1)] and findings in animal studies, arsenic trioxide injection can cause fetal harm when administered to pregnant woman. Arsenic trioxide was embryolethal and teratogenic in rats when administered on gestation day at dose approximately 10 times the recommended human daily dose on mg/m basis (see Data). related trivalent arsenic, sodium arsenite, produced teratogenicity when administered during gestation in mice at dose approximately times the projected human dose on mg/m basis and in hamsters at an intravenous dose approximately equivalent to the projected human daily dose on mg/m2 basis. There are no studies with the use of arsenic trioxide injection in pregnant women, and limited published data on arsenic trioxide use during pregnancy are insufficient to inform drug-associated risk of major birth defects and miscarriage. Advise pregnant women of the potential risk to fetus.The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.Data Human Data One patient was reported to deliver live infant with no reported congenital anomalies after receiving arsenic trioxide during the first five months of pregnancy. second patient became pregnant three months after discontinuing arsenic trioxide and was reported to have normal pregnancy outcome. third patient was pregnant healthcare provider who experienced dermal contact with liquid arsenic trioxide and had normal pregnancy outcome after treatment and monitoring. fourth patient who became pregnant while receiving arsenic trioxide had miscarriage.Animal Data Studies in pregnant mice, rats, hamsters, and primates have shown that inorganic arsenicals cross the placental barrier when given orally or by injection. An increase in resorptions, neural-tube defects, anophthalmia and microphthalmia were observed in rats administered 10 mg/kg of arsenic trioxide on gestation day (approximately 10 times the recommended human daily dose on mg/m2 basis). Similar findings occurred in mice administered 10 mg/kg dose of related trivalent arsenic, sodium arsenite (approximately times the projected human dose on mg/m2 basis), on gestation days 6, 7, 8, or 9. Intravenous injection of mg/kg sodium arsenite (approximately equivalent to the projected human daily dose on mg/m2 basis) on gestation day (the lowest dose tested) resulted in neural-tube defects in hamsters.